

## EATRIS ESPAÑA CASOS DE ÉXITO





**David Velasco & M Laura Garcia Bermejo**

National Coordinator & National Director EATRIS Spain (EATRIS ES)

# EATRIS ES – Retornos económicos y participación: nodo español como caso de éxito

### Evolución de los retornos económicos nodo español



**Tercer año consecutivo**

# EATRIS ES – Casos de éxito



trustroke

## TRUSTWORTHY AI FOR IMPROVEMENT OF STROKE OUTCOMES

Una nueva plataforma basada en inteligencia artificial para el manejo de las fases aguda y crónica del accidente cerebrovascular isquémico.



**Vall d'Hebron**  
Institut de Recerca





# EATRIS ES – Contribución clave a EATRIS Flagships



VHIR



IGTP, IDIPAZ, VHIR



IIS La Fe, IRYCIS



IRYCIS, VHIR



IIS Aragón, IDIS, VHIR,  
IIS LA FE, IDIVAL, IGTP



trustroke

VHIR




IRYCIS

New Applications:

- IHI: ATMPs
- INFRADEV: EATRIS Connect y AMRI
- HTH Topics

# EATRIS ES – Cooperación con otras infraestructuras



European Alliance of Medical Research Infrastructures

EU-AMRI

EuAmri

www.eu-amri.org

**AMRI-EU: SPAIN PROPOSAL**

EU-AMRI is a European Alliance of Medical Research Infrastructures (MRI), which integrates three research infrastructures (RI): BBMRI-ERIC, EATRIS-ERIC, and ECRIN-ERIC. This alliance has been launched in 2021 for offering services in a comprehensive and integrative manner to biomedical researchers. It is made up of 29 European countries, members and observers of AMRI, including more than 700 research institutes and university hospitals. Based on the nature of the three AMRI components, this alliance represents an unprecedented framework for translational and clinical research, including Personalized Precision Medicine (PPM) development and implementation in the European landscape.

Spain is one of the few countries in Europe where this RI-collaboration is already established. The most prestigious Spanish institutions for translational and clinical research include SCIN (ECIN node), Biobank and Bio-models and EATRIS operational units. Moreover, translational and clinical research, for which the three MRIs are essential in providing services, is one of the strengths of Spanish contribution to the global science development. Therefore, Spain offers an excellent scenario for reinforcing and making sustainable AMRI alliance. In addition, AMRI Spain could be a driver for clinical research democratization and equity between Spanish regions, guaranteeing the offer of services of excellence to Spanish patients and citizens across the country.

AMRI-Spain (AMRI-ES) building under Instituto de Salud Carlos III (ISCIII) umbrella will be based on common activities addressed by the three MRIs. To that, all the actions will be exclusively developed in a synergistic and collaborative manner. AMRI Spain strategy will be aligned with other strategic national initiatives and platforms in biomedical research, particularly, those launched by ISCIII and devoted to Personalized Precision Medicine (PPM) implementation, including IMPACT, Independent Clinical Research Initiative (ICI) and Personalized Medicine Program. This orientation represents an ideal demonstrator of the current and future coordination of the three MRIs.

**Objectives to be considered into AMRI Spain strategy could include:**

**Objective 1: Building of a common services catalogue of AMRI-ES to be offered to the Research Community.**

- Task 1: Mapping individual and common capacities of the three RIs
- Task 2: Exploring synergies in existing RIs capacities
- Task 3: Exploring new offers based on common capacities
- Task 4: Identifying common strategic priorities and business models for PPM across the AMRI nodes
- Task 5: Establishing coordination workflows and procedures between the 3 RIs for a sustainable develop of AMRI-ES Node
- Task 6: Defining and establishing KPIs for AMRI-ES activities follow-up, monitoring and implementation with a particular focus on coordination activities and added value.

**Objective 2: Create awareness of AMRI Spain (AMRI-ES)**

- Task 1: Participating as alliance in strategic, national and International calls
- Task 2: Co-creation and building own proposals for PPM development in the national scenario

**Objective 3: Dissemination and outreach policy**

- Task 1: Generating common operating procedures and pipelines to corroborate and implement workflows across MRIs and belonging institutions
- Task 2: Building the Open AMRI-ES toolbox for reviewing, implement and monitor PPM development in any national institution
- Task 3: Delivering of common quality assessment programs accessible for PPM developers and users
- Task 4: Delivering of AMRI-ES position documents for AMRI-ES services and impact in PPM

**Objective 4: Education and training AMRI-based**

- Task 1: Elaborating common education and training programs and activities in services, quality assessment, ethics and patient-engagement, internal AMRI-ES summer schools, specific courses
- Task 2: Aligning AMRI-ES education programs with other national initiatives contributing to PPM implementation
- Task 4: Establishing Staff Exchange programs between RIs and institutions for expanding AMRI concept and contributing to PPM education of new research generation
- Task 5: Building education and training activities with other IEC other external activities in complementarity in the Spanish Biomedical R&D.

**Objective 5: Alignment with AMRI-EU reinforcing the international MRI cooperation**

- Task 1: Including the AMRI-ES services strategies into AMRI-EU
- Task 2: Offering the AMRI-ES-based portfolio to international academy and industry partner for development of PPM-based solutions
- Task 3: Expanding AMRI-ES staff exchange program to other AMRI-Nodes in Europe
- Task 4: Launching common education programs with AMRI-EU for training the new European research generation responsible for PPM implementation.



# EATRIS ES – Centros Expertos EATRIS



**Application form for EATRIS Institution to be EATRIS Expert Services provider**

Application Date:	
EATRIS Institution:	
Contact person (name):	
Email:	
Department:	
Head of the Institution:	
Address/City:	
Country:	
Local National Director:	
Authorization received from national node representatives (BoG and/or BoND)	<input type="checkbox"/> yes <input type="checkbox"/> not needed under national procedure
Decentralised Services* to be provided (check appropriate box/es)	<input type="checkbox"/> Innovation Management <input type="checkbox"/> Translational Feasibility Assessment <input type="checkbox"/> Regulatory Support <input type="checkbox"/> (Early) Health Technology Assessment <input type="checkbox"/> Other _____ <small>* please attach to this Application Form, if available, any flyers and/or leaflets you may have on the Services</small>
Expertise and track record	<small>(please describe here relevant expertise in specified Service field, associated expert staff*)</small>



# EATRIS ES – Formación, participación ciudadana y patient engagement



**ADVANCE**  
Next Generation of Advanced Therapies Specialists

**An Innovative & Focused Learning Programme for Future ATMP Developers**

By establishing an innovative and focused learning programme, ADVANCE aims to establish a strategic partnership between key players from education, research and industry who contribute to the innovation of ATMPs (Cell & Gene Therapies) to jointly develop curricula for early-career biomedical professionals.

ADVANCE Programme Curriculum focuses on specific skills and knowledge in 4 key areas of ATMPs development:

- Scientific
- Manufacturing
- Regulatory
- Commercialisation/ Reimbursement

**Key facts**

- 5-Day Workshops
- Recorded Webinar Series
- Self-paced Online Course (3-7h)
- Individual Career Coaching
- Accreditation: Open Badges & ECTS
- Free of charge

**EATRIS-Plus Summer School in Personalised Medicine**

23-26 May 2022

**EATRIS-Plus Summer School in Personalised Medicine**

17-20 April 2023

**peof** Patient Engagement Open Forum 2022  
October 3-5, 2022 | Barcelona, Spain

**3 October, 14:00 - 21:00 (including dinner)**

**14:30 - 14:30 Welcome opening & registration**

**14:30 - 15:20 Welcome plenary:** Take stock of PE's fast-moving pace and work on the next chapters together. **Speakers including:** Nicholas Brooke (Pfizer), Maria Duarte (EUPA), Valentina Strommelle (EPF), Simone Johnson (Patient Advocate)

**15:20 - 17:00 Engaging theory and practice for patient representation:** Are you curious about the practical application of the Global Harmonisation Principles in your everyday work? Are you looking for tools to facilitate open and transparent dialogues around representation for patient-oriented research? Join us for practical workshops to test the co-created global harmonisation frameworks and shape the development of a digital tool to support structured and open dialogue on patient representation practices. **Speakers and workshop facilitators including:** Barbara Neubauer (Patient Advocate), Nicole Wicki (Pfizer), Laura McKeowney, Simone Johnson (Patient Advocate), Kay Warner (EPF), Andrew Downey (EPF), Siska Berneburg (Pfizer)

**17:00 - 17:00 Parental Research:** Taking action to engage pediatric and young patients in innovative clinical trials. Pediatric and young people have their own voices and deserve to actively participate and understand the principles of innovative clinical trials. This session reflects on the challenges and barriers for pediatric and young patients' involvement in innovative clinical trials and brings the opportunity to listen to different individuals. **Speakers including:** Tessa Bell (Patient Representative), Esther Meis Business Developer, Pediatric Forces of Digital Health), Dr. Bob Phillips (The Leeds Teaching Hospitals, NHS Trust), Dr. Birco Lohmann (Former member of the Federal Institute for Drugs and Medical Devices, Germany, BfArM)

**17:00 - 17:00 Early in translation: patient engagement in early discovery and pre-clinical research:** There is a lot of guidance for patient engagement in clinical research, but there is little support that drives early engagement in laboratory and pre-clinical settings. This session will explore tactics to enable engagement of patients in early stage research. **Speakers including:** Louise Azevedo (Prethous AG), Emma Davis (UCSF), Valentina Strommelle (EPF), Anne-Chantal Faurel (EATRIS), Idoiev Vot (Pfizer)

**17:00 - 17:00 Coffee break**

**17:30 - 18:30 Building a dialogue - a reference point for patient engagement (Start of Good Practices):** We invite you to a small networking activity, where we hope to hear what you are celebrating at PEOP. We will also discuss how PEOP can further become a lightsource for PE, providing a reference point for quality patient engagement in this fast-changing landscape. Join us for stress & informal talks. **Activity organisers:** Daniela de Scheepster (A&L), Paula Wray (University of Oxford), Idoiev Vot (Pfizer), Maria Aze (Pfizer)

**18:00 - 21:00 Shared sponsored welcome dinner**

Powered by:

October Event Sponsored by:



Patient Engagement

**eatris** [About](#) [Services](#) [Projects](#) [Platforms](#) [News](#) [Events](#) [Resources](#) [Contact](#)

Discover the landscape of translational medicine from leading experts

5 days, 9:00-17:00 CEST

13-17 February 2023

Palau Macaya, Barcelona

PhD/MD students, postdocs

**TMEX - TRANSLATIONAL MEDICINE EXPLAINED 5 DAY WINTER SCHOOL 2023**

**eatris** "Success stories on biomarkers: from bench to the clinical practice"

**16:00h** Joan Comella (ND EATRIS ES), Cláudia Faria (ND EATRIS PT) - Welcome and Introduction

**16:10h** Hugo Prazeres (IR3) - The limitless potential of Telomerase in non-invasive monitoring of urothelial carcinoma of the bladder

**16:30h** Bruno Costa (UMINHO) - New prognostic biomarkers in glioblastoma

**16:50h** Josep Quer (VHIR) - Diagnostic solutions for Hepatitis C virus (HCV) based on Next-generation sequencing (NGS)

**17:10h** Inmaculada Ibañez (IDIPAZ) - miR7-MAG axis associated aptamer technology for the diagnosis and treatment of Non-small-cell lung carcinoma (NSCLC)

**17:30h** Round table: speakers + Toni Andreu (EATRIS)

Moderator: Emanuela Oldoni (EATRIS)

**eatris+** The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 871599.

## BM-VIIM workshop, June 28th

Time	What	Who
09:00-09:05am	Welcome from EATRIS	David Morrow
09:05-09:20	Welcome from the EATRIS Platform chairs	Laura Bermejo, Alain van Gool, Jan Langermans
<b>Keynotes (chair: Emanuela Oldoni)</b>		
09:20-10:00 am	<b>Round table:</b> Unmet medical needs and the patient perspective- Discussion between clinicians and patient	Maria Ruiz-Ruigomez (I12) Lydia Laranzabal (IRYCIS) Julia Prado (IGTP)
10:00-10:25 am	<b>Keynote - Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition</b>	
<b>Pitches (chair: David Morrow)</b>		
10:25-10:35 am	Pitch 1 Perspectives on long Covid from Bergen Norway	Rebecca Cox, Nina Langeland (UmiBj)
10:35-10:45 am	Pitch 2 - Molecular phenotyping of the pulmonary post-acute sequelae in critical COVID-19	David de Gonzalo, Ferran Barbe (IRB Leida)
10:45-10:55 am	Pitch 3- Genetic risk factors for Long COVID	Lammi Vilma (FIMM)
11:00-11:20 am	<b>Coffee break</b>	
11:20-11:30 am	Introduction to the COST action call	Emanuela Oldoni
11:30-12:50 am	General discussion- concept for COST action	Alain van Gool
12:50-13:00 am	Conclusions and Adjourn	Jan Langermans

Patient Engagement  
RESOURCE CENTRE



## Contactos:

David Velasco, NC: [d.velasco@isciii.es](mailto:d.velasco@isciii.es)

M Laura García-Bermejo, ND:  
[garciabermejo@gmail.com/direccion.irydis@salud.madrid.org](mailto:garciabermejo@gmail.com/direccion.irydis@salud.madrid.org)



EATRIS



@EatrisEric



[www.eatris.eu](http://www.eatris.eu)



Translational Trends

